Skip to main content
All lobbying filings

WILLIAMS AND JENSEN, PLLC

Lobbying for NOVOCURE INC. · Commercial stage oncology dedicated to advancement of TTF therapy to treat solid tumors.

 Filing 4th Quarter - Report
Reporting period
4th Quarter 2025
Oct 1 - Dec 31 · Posted Jan 20, 2026
Income
$60,000.00
What the client paid this registrant for the period.
Client based in
New Hampshire

Official filing document

 Lobbyists on this filing 3
  • JEANNE HAGGERTY New on this filing
    Previously held: Legislative Correspondent Senator Chuck Grassley and Senate Aging Committee (shared staff), Legislative Aide Senate Finance Committee, Health Policy Coordinator Health Subcommittee Energy and Commerce, Professional Staff Member
  • ROBERT BUTORA New on this filing
    Previously held: Health Policy Advisor, Senator Bill Cassidy; Senior Health Policy Advisor, Representative Leonard Lance, Health Legislative Assistant, Representative Michael Burgess
  • DANIEL ZIEGLER New on this filing
    Previously held: Executive Director, Republican Study Committee; Legislative Director for Rep Doug Lamborn, Policy Director; Speaker Mike Johnson

A "covered position" is a government job the lobbyist held in the 20 years before registering, which the law requires them to name. See the revolving door for former members of Congress across all filings.

 Government bodies contacted 2
  • HOUSE OF REPRESENTATIVES
  • SENATE

The chambers, agencies and offices the filer named. It does not say who inside them was contacted, or when.

 Bills named in this filing 2
  • HR 5343
    Ensuring Patient Access to Critical Breakthrough Products Act
  • S 1717
    Ensuring Patient Access to Critical Breakthrough Products Act of 2025
 Lobbying activity 2
Pharmacy

Breakthrough pathway bill (H.R. 5343, S. 1717), CMS reimbursement of medical devices generally, and FDA issues related to medical devices.

Medicare/Medicaid

Breakthrough pathway bill (H.R. 5343, S. 1717), CMS reimbursement of medical devices generally, and FDA issues related to medical devices.

 Foreign interests disclosed 2

Section 7 of the LD-2: foreign entities that own part of the client, paid toward this lobbying, or stand to benefit from it.

  • NOVOCURE GMBH
    Switzerland · 6340 Baar · owns 100% of the client · contributed $0.00
  • NOVOCURE LUXEMBOURG S.A.R.L. (OWNS 100% OF NOVOCURE GMBH)
    Luxembourg · L-1273, Luxemborg · owns 100% of the client · contributed $0.00

Source: federal Lobbying Disclosure Act filing, reproduced as filed. Bills are parsed from the activity descriptions.

Report a problem